FDA Voluntary Recall of Methylprednisolone Tablets for Subpotency
Jubilant Cadista Pharmaceuticals is recalling Methylprednisolone Tablets USP 4mg because they contain less active ingredient than labeled. Lot 21 P0322 was distributed nationwide and in Puerto Rico.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III voluntary recall with no reported illnesses or injuries. Per the rubric, Class III recalls are typically scored as 1 or 2; voluntary precautionary recalls are classified as Moderate (2). Subpotency is a manufacturing defect affecting drug efficacy, but poses no immediate physical danger.
Plain-English summary
Jubilant Cadista Pharmaceuticals, Inc. has recalled one lot of Methylprednisolone Tablets, USP 4mg in 100-count bottles due to subpotency. The tablets were found to contain less active ingredient than the labeled amount of 4mg per tablet.
Lot 21 P0322 with expiration date 01/2023 was distributed nationwide in the United States and Puerto Rico. Approximately 19,222 bottles (100-count) were affected. The manufacturer initiated the recall on April 1, 2022, and the FDA terminated the recall on April 3, 2023.
Patients taking this medication who have concerns should consult their healthcare provider. Individuals with the recalled product should contact the manufacturer or speak with their pharmacist about returning or replacing the affected bottles.
This was a Class III voluntary recall, which is the lowest FDA priority category for drug recalls.
The recalled product
- Product
- Methylprednisolone Tablets, USP 4mg, 100-count bottle, Rx Only, Manufactured by: Jubliant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-001-06
- Manufacturer
- Jubilant Cadista Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 21 P0322
- Exp. 01/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27